Straumann Group (STMN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
29 Apr, 2026Executive summary
Q1 2026 revenue reached CHF 673 million, representing 7.1% organic growth year-over-year, with all regions and segments contributing positively despite a 1.2% decline in CHF due to FX headwinds.
Strongest regional growth in Latin America (19.5%), followed by EMEA (7.8%), North America (7.7%), and APAC (0.5%, over 10% excluding China), with stabilization in Asia Pacific amid China headwinds.
Market share increased to 14% in a CHF 20 billion market, with leadership in implantology, orthodontics, and digital equipment, supported by innovation and digital transformation.
Strategic focus on operational excellence, commercial execution, and team engagement is driving resilience and market share gains.
Financial highlights
Organic revenue growth of 7.1% was offset by a reported decline of 1.2% in CHF due to a CHF 53 million negative FX impact, mainly from USD and EUR depreciation.
EMEA contributed 47% to group revenue growth, North America 28%, and Latin America 23%.
Dividend increased to CHF 1.00 per share, a 5% rise, with a payout ratio of around 33%, supported by strong cash generation.
Investments in manufacturing and supply chain, including the Shanghai campus ramp-up, are yielding cost efficiencies and reducing FX exposure.
Margin guidance for 2026: core EBIT margin improvement of 30–60 basis points at constant 2025 FX rates.
Outlook and guidance
High single-digit organic revenue growth and core EBIT margin improvement of 30–60 basis points at constant exchange rates are expected for 2026.
Market conditions remain volatile due to macroeconomic, geopolitical, and regulatory uncertainties, but confidence in guidance is supported by a resilient business model and diversified footprint.
FX headwind expected to moderate over the year; full-year FX impact on margin estimated at 100–120 basis points at March spot rates.
Latest events from Straumann Group
- 8.9% organic revenue growth, strong margins, and digital-driven innovation in 2025.STMN
Q4 202511 Apr 2026 - Targeting 10% CAGR and margin gains through digital innovation, multi-brand growth, and efficiency.STMN
CMD 20253 Feb 2026 - Strong H1 growth, robust margins, and digital focus drive positive outlook after DrSmile sale.STMN
Q2 20241 Feb 2026 - Q3 organic revenue rose 11.2% to CHF 585.5M, with 2024 outlook for double-digit growth confirmed.STMN
Q3 202418 Jan 2026 - 13.7% organic revenue growth to CHF 2.5B, strong global gains, and higher dividend proposed.STMN
Q4 20248 Jan 2026 - Q1 2025 delivered 11% organic growth, led by APAC, EMEA, and digital innovation, with outlook confirmed.STMN
Q1 202529 Nov 2025 - 10.2% organic revenue growth and robust digital momentum drive strong H1 2025 results.STMN
Q2 202523 Nov 2025 - Q3 2025 delivered 8.3% organic growth, strong EMEA/LATAM gains, and confirmed margin outlook.STMN
Q3 202529 Oct 2025